In his weekly clinical update, Dr. Griffin discusses wastewater surveillance data as a complement to emergency department visit data for tracking the incidence of influenza A and RSV, chatbot-delivered online intervention to promote seasonal Influenza vaccination during the COVID-19 pandemic, temporal assessment of disparities in California COVID-19 mortality by industry, modeling the impact of a high-uptake bivalent booster scenario on the COVID-19 burden and healthcare costs in New York City, can high COVID-19 vaccination rates in adults help protect unvaccinated children, Nirmatrelvir/Ritonavir use and hospitalizations or death in previously uninfected non-hospitalized high-risk population with COVID-19, Optimal duration of systemic corticosteroids in COVID-19 treatment, and vaccination after developing long COVID.
In his weekly clinical update, Dr. Griffin discusses the immunogenicity and reactogenicity of coadministration of COVID-19 and Influenza vaccines, interim effectiveness estimates of 2023 southern hemisphere influenza vaccines in preventing Influenza-associated hospitalizations, genome-wide association study of susceptibility to RSV hospitalization in young children <5 years of age, performance of rapid antigen tests to detect symptomatic and asymptomatic SARS-CoV-2 infection, safety and immunogenicity of XBB.1.5-containing mRNA vaccines, optimal duration of systemic corticosteroids in COVID-19 treatment, timing and predictors of loss of infectivity among healthcare workers with mild primary and recurrent COVID-19, and effects of famotidine on cognitive and behavioral dysfunctions induced in post-COVID-19 infection.
In his weekly clinical update, Dr. Griffin discusses China’s health authorities fighting surge in cases of Mpox unknown origin, analysis of seasonal variation of antibiotic prescribing for respiratory tract diagnoses in primary care practices, prevalence and associated outcomes of co-infection between SARS-CoV-2 and influenza, comparison of bivalent and monovalent mRNA vaccine boosters, optimal duration of systemic corticosteroids in COVID-19 treatment, acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization, temporal changes in fecal microbiota of patients infected with COVID-19, and long-term survival after intensive care for COVID-19.
In his weekly clinical update, Dr. Griffin discusses modeling poliovirus transmission and responses in New York State, FDA approves first vaccine for pregnant individuals to prevent RSV in infants, prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Cmmittee on Immunization Practices, Nirmatrelvir resistance – de novo E166V/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir/ritonavir monotherapy leading to clinical and virological treatment failure, incidence of new-onset hypertension post–COVID-19: comparison with influenza, and post-acute sequelae of COVID-19 at 2 years.
In his weekly clinical update, Dr. Griffin discusses Florida local transmission of dengue cases reported in Broward and Miami-Dade counties, infants admitted to US intensive care units for RSV infection during the 2022 seasonal peak, long-term risk of death and readmission after hospital admission with COVID-19 among older adults, safety profile and clinical and virological outcomes of Nirmatrelvir-Ritonavir treatment in patients with advanced chronic kidney disease and COVID-19, Fluvoxamine vs placebo for outpatients with symptomatic COVID-19, the effect of corticosteroids, antibiotics, and anticoagulants on the development of post-COVID-19 syndrome in COVID-19 hospitalized patients 6 months after discharge, long COVID and significant activity limitation among adults, incidence of diabetes following COVID-19 vaccination and SARS-CoV-2 infection in Hong Kong, and diabetes following SARS-CoV-2 infection: Incidence, persistence, and implications of COVID-19 vaccination.
In his weekly clinical update, Dr. Griffin discusses the immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate, association between nose picking and SARS-CoV-2 incidence, a cohort study in hospital health care workers; effect of COVID-19 vaccination and booster on maternal-fetal outcomes, dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA, does monoclonal antibody treatment for COVID-19 impact short and long- term outcomes in a large generalizable population, persistent endothelial dysfunction in post-COVID-19 syndrome and its associations with symptom severity and chronic inflammation, core mitochondrial genes are down-regulated during SARS-CoV-2 infection of rodent and human hosts.
In his weekly clinical update, Dr. Griffin discusses predicting COVID-19 incidence using wastewater surveillance data, use of wastewater metrics to track COVID-19 in the US, wastewater-based epidemiology predicts COVID-19-induced weekly new hospital admissions in over 150 USA counties, association between duration of SARS-CoV-2 positivity and long COVID, rapid direct detection of SARS-CoV-2 aerosols in exhaled breath at the point of care, effectiveness of oral Nirmatrelvir/Ritonavir vs. intravenous three-day Remdesivir in preventing progression to severe COVID-19, NIH launching of several phase 2 long-COVID treatment trials.
In his weekly clinical update, Dr. Griffin discusses the transmission of SARS-CoV-2 in free-ranging white-tailed deer in the United States, Omicron subvariant BA.5 efficiently infects lung cells, COVID-19 scent dog research highlights and synthesis during the pandemic of December 2019, T-Cell Immunity against SARS-CoV-2 measured by an interferon-γ release assay is strongly associated with patient outcomes in vaccinated persons hospitalized with Delta or Omicron variants, a common allele of HLA is associated with asymptomatic SARS-CoV-2 infection, and the immunology of long COVID.
In his weekly clinical update, Dr. Griffin discusses the new risk assessment for the H5N1 avian flu viruses, the development of monoclonal antibody-based blocking ELISA for detecting SARS-CoV-2 exposure in animals, repeated antibiotic exposure and risk of hospitalization and death following COVID-19 infection, COVID-19 rebound study: a prospective cohort study to evaluate viral and symptom rebound differences in participants treated with Nirmatrelvir plus Ritonavir versus untreated controls, exaggerated blood pressure elevation in response to orthostatic challenge a post-acute sequelae of SARS-CoV-2 infection (PASC) after hospitalization, long term follow-up of a multicenter cohort of COVID-19 patients with pulmonary embolism, and risk of cardiovascular disease after COVID‐19 diagnosis among adults with and without diabetes.
In his weekly clinical update, Dr. Griffin discusses autochthonous leprosy in the United States, a systematic review to identify novel clinical characteristics of Mpox virus infection and therapeutic and preventive strategies to combat the virus, two-year duration of immunity of inactivated poliovirus vaccine, evaluation of novel oral polio vaccine type 2 SIA impact in a large outbreak of circulating vaccine-derived poliovirus in Nigeria, performance of rapid antigen tests to detect symptomatic and asymptomatic SARS-CoV-2 Infection, effectiveness of the COVID-19 bivalent vaccine, oral Nirmatrelvir and Ritonavir for COVID-19 in vaccinated, non-hospitalized adults ages 18-50 years, genome-wide association study of long COVID, vaccination ameliorates cellular inflammatory responses in SARS-CoV-2 breakthrough infections, and high incidence of autonomic dysfunction and postural orthostatic tachycardia syndrome in patients with long-COVID.